$INNV | An Undervalued Pharma Company with Strong Commercial Pipeline and Solid Revenues
21 Mar
2016
Written by Mike Elliott

$INNV | An Undervalued Pharma Company with Strong Commercial Pipeline and Solid Revenues »

In this episode of the CEOLIVE.TV Investor Profile Series we interview Dr. Bassam Damaj, CEO of Innovus Pharmaceuticals. Dr. Damaj discusses recent acquisitions, the company's strong commercial pipeline and why Innovus Pharmaceuticals (INNV) is undervalued right now.

Read more...

Login

Lost your password?